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Osteoarthritis (OA) is the most common 
musculoskeletal disease, where the pathogenesis is 
still not known well, but it is currently developing 
several hypotheses and theories are still debatable.1,2 
OA formerly regarded as a non-inflammatory 
diseases caused by degenerative disease due to 
increasing age, but along with the development 
of research, it is known that OA is fairly complex 
disease, multifactorial causes, although the etiology 
is not well known, and the disease also occurs as 
a result of not severe acute inflammation.2 World 
Health Organization (WHO) estimates that 10% 
of the entire population over the age of 60 years 
suffer from this disease. OA and other rheumatic 
diseases affecting more than 43 million people in 
the United States in 2020 and is expected to reach 
to 60 million patients.3,4 The study in UK shows the 
OA incidence is 25% per year, with the prevalence 
of disability due to knee OA is 10% and the severe 
disability as much as 5%.5
 OA is also causing high socio-economic 
impact, both in developed countries as well as in 
developing countries, including Indonesia.6,7,8 It is 
estimated that one to two million elderly people in 
Indonesia suffer from disability due to OA. In the 
next century, the challenge of the OA impact will 
be even greater in elderly population.9,10
Currently, OA is characterized by the damage to 
the joint cartilage gradually accompanied by the 
presence of joint inflammation. OA can affect 
any joint, but is more common in the knees, hips, 
spine and hands.2,11-13 Pain is the main complaint of 
patients with osteoarthritis. Therefore, in general, 
the aims to the treatment of OA are to reduce pain, 
to prevent deformity, to improve quality of life, 
and to provide knowledge to the people about the 
disease.  
 The pathogenesis of OA is not only a 
degenerative process, but also inflammation. Joint 
pain, tenderness, limited range of motion, crepitus 
and swollen, increase intra-articular pressure, 
ABSTRACT
Background: Osteoarthritis (OA) is the most common 
musculoskeletal disease. World Health Organization 
(WHO) estimates that 10% of the aged over 60 year 
population have this disease. The aim of OA treatment 
is to reduce pain, which is the most OA patients chief 
complaint. People in Indonesia are very interested in use 
of herbal therapies from original traditional plant to treat 
pain now, one of the traditional plants that are known have 
a benefit is Phaleria macrocarpa or Mahkota Dewa fruit. 
Phaleria macrocarpa has been shown to decrease the 
degree of inflammation of OA animal model experiments. 
In order to know what is the effect of this fruit extract 
to reduce degrees of pain and change the levels of IL-1, 
IL-6, TNF-α in the blood as the marker of inflammation of 
patients with knee OA, and what is the effects to liver, 
kidney and haematology in the Indonesian population has 
not been investigated.
Methods: The research method is an experimental 
study and the research design is PROBE (Prospective 
Randomized Open End Blinded Evaluation), to evaluate 
the efficacy of the extract Mahkota Dewa fruit (Phaleria 
macrocarpa fructus) 330 mg (Super Mahkota POM 
TR 053 345 491) compared to meloxicam 7.5 mg in 
patients with knee osteoarthritis. The study population 
was outpatients with knee OA at Rheumatology Clinic 
Dr Hasan Sadikin Hospital Bandung. Patients are given 
Phaleria macrocarpa 330 mg or meloxicam 7.5 mg once 
a day for 14 days. Observations were made to evaluate 
the degree of pain as measured by VAS and Lequesne 
index at day 0, day 14 and measured again at day 28, 
after they are not taking the extract anymore. 
Results: Phaleria macrocarpa 330 mg is equal to 
meloxicam 7.5 mg in reducing the degree of pain as 
measured by VAS (p=0.78) and the Lequesne index 
(p=0.51). Our finding, there is no effect of decreasing 
the proinflammatory cytokine IL-1 (p=0.72), IL-6 
(p=0.53) and TNF-α (p=0.07) in the blood of both 
groups. Safety analysis shown that this extract is safe 
for consumption.
Conclusions: Phaleria macrocarpa 330 mg equal 
to meloxicam 7.5 mg in reducing the degree of pain 
however there is no effect on reducing proinflammatory 
cytokines in the blood of OA patients who had received 
therapy for 14 days in both groups. There is no adverse 
effects found on hematological, liver function and kidney 
Original Article
21Indonesian Journal of Rheumatology 2016; Vol 8
changes in the structure of the joints and tissue debris cause 
inflammation of the synovial membrane, capsule, tendon, 
and bursa. Proinflammatory cytokines such as IL-1, IL-6 and 
TNF-α are found to be high in the synovial fluid of the knee 
OA patients.11,12,17,18
 Pharmacologic therapy in knee OA is divided into two main 
outcomes. The first, to reduce pain by analgesics, nonsteroidal 
anti-inflammatory drugs (NSAIDs), intra-articular injections, 
steroids, hyaluronan acid. The second, drugs used to inhibit 
the progression of OA are Modifying Osteoarthritis Drugs 
(DMOADs). DMOADs work by maintaining structural 
balance and stimulate the growth of cartilage cells of cartilage. 
Several studies have found that these drugs also have anti-
inflammatory effects.11,12,14,16
 Nowadays people are very interested in the use of herbal 
therapies derived from traditional plant. One of the traditional 
plants that are known to have benefits is Phaleria macrocarpa 
or mahkota dewa.19,20
 Mahkota Dewa fruit extract (Phaleria macrocarpa fructus) 
has been shown to reduce the degree of OA in animals, because 
the structure of the active substance similar to ketoprofen. 
Mahkota Dewa fruit ethanol extract with the doses of 15; 
22.5; and 30 mg/kg bw mice can reduce levels of interleukin-
1β and TNF-α serum -induced arthritis in mice kolagen.21,22 
Study in human clinical trials have not been conducted, but as 
a process of standardization we get a dose of Mahkota Dewa 
fruit extract 330 mg per day according to animal study doses.
Methods
The study design was an experimental research, the research 
design is Prospective Randomized Open-label Blinded at 
End Experimental (PROBE) to evaluate the efficacy of the 
mahkota dewa fruit extract 330mg (Super Mahkota, POM: TR 
053 345 491) compared to 7.5 mg meloxicam as control group 
in patients with osteoarthritis.
 The study population was patients with OA at the 
Rheumatology Outpatient Clinic in Dr. Hasan Sadikin 
General Hospital who live around Bandung city. Then sample 
was taken by simple random sampling methods to establish a 
research subject. 
 Inclusion criteria are patients with knee OA based on the 
consensus of the Indonesian Rheumatology Association (IRA), 
based on clinical (joint pain) and radiological (osteophytes), 
with at least 1 of the following 3 criteria: stiffness less than 
30 minutes, age more than 50 years, crepitus on active joint 
motion; patients with OA pain intensity scores 2–7 according 
to Visual Analogue Scale (VAS). Exclusion criteria are there 
are other comorbidities: COPD, cardiac decompensation, 
walking disability was not caused by knee OA; undergoing 
medical rehabilitation; history of allergy to meloxicam or 
mahkota dewa; AST and ALT exceed twice the upper limit, 
normal creatinine > 1.1 mg/dl; using NSAIDs and oral or 
steroid injection 2 weeks or 3 months before the study.
 Visual Analogue Scale (VAS) questionnaire is the most 
easy tool to be used by interviewer to determine the degree of 
pain that experienced by OA patients in numbers. Lequesne 
index for knee OA, also known as (Index of severity for knee 
OA), was originally developed in French and also in other 
languages such as German, Korea and Singapore. This index 
has been studied can be used in Asia and has been proven 
valid in Southeast Asian populations. This index consists of 11 
questions divided into three sections, five questions relating to 
pain, two questions about distance running, and four questions 
about the ability of daily activity or quality of life.47
 Radiological examination is sufficient to support the 
diagnosis, and also the degree of OA can be classified based on 
the radiological features. Semi-quantitative assessment done 
by Kellgren-Lawrence radiographic criteria and Osteoarthritis 
Research Society International (OARSI).44
 Test material in this study is the mahkota dewa fruit 
extracts that have been carried out which one of them is the 
standardization of assay in accordance with the applicable 
regulations in Indonesia. This herbal remedy has been 
registered, with the trademark “Super Mahkota”, which is 
registered under number : POM TR 053 345 491, in the form 
of capsules containing 330 mg of extract Phaleria macrocarpa 
each capsule.23,24
 Patients treated by Mahkota Dewa fruit extract capsules 330 
mg once a day for 14 days, in the treatment group and 7.5 mg 
meloxicam once a day in the control group. Observations were 
made of the pain degree as measured by VAS and Lequesne 
index, which was performed before and after administration 
of Mahkota Dewa fruit extract. If the patients experienced 
pain during administration of the test material (VAS > 7), then 
they can be given an additional 500 mg paracetamol orally at 
the beginning to 4000 mg per day orally (rescue medication). 
 On day 1 and 14, blood samples were taken to measure 
the levels of IL-1, IL-6 and TNF-α. VAS and Lequesne index 
measured on day 14 and 28. Liver function measured with AST 
and ALT examination, renal function examination with ureum 
and creatinine, hematology examination with hemoglobin, 
leukocyte count, platelet count.
 Kolmogorov-Smirnov test of Goodness of Fit performed 
to determine the normality of the distribution of the data. 
Statistical analysis done by t test for data ratio or interval 
scale who normally distributed. To compare the data pairs in 
the experimental group used the Wilcoxon Z test. Level of 
significance is determined by the value of p <0.05.
Results
This study subjects were 42 patients. Six subjects were 
excluded from this study, because one person has other 
diseases like gout arthritis, one person does not follow the 
rules of taking the medication and four patients had dropped 
out.
 Of the 36 patients who completed the study 19 patients 
had Mahkota Dewa fruit extract 330 mg in each capsules 
and 17 patients had Meloxicam 7.5 mg. Average age of knee 
OA patients was 59.1 years old. Most of the study subjects 
were women (85.7%), aged between 45 to 69 years old. The 
severity of radiological OA mostly located in the first degree 
(45.2%) and second degree (42.9%).
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Table 1 Characteristics of OA patient according to group of 
treatment
Variable
Treatment Group
Mean (SD)/N(%) P value
Phaleria Macro-
carpa 330 mg
Control
Meloxicam
7.5 mg
Age (year)
     Median
Gender :   
     Women
OA degree
   I
   II
   III
IL-1      (pg/ml)
IL-6      (pg/ml)
TNF-α (pg/ml)
Hb        (gr/dl)
Leukocyt (/mm3)
Trombocyt (x1000/mm3)
AST (U/L) 
ALT (U/L)
Ureum (mg/dl)
Creatinine (mg/dl)
BMI
60.24 (5.69)
59.00
19 (90.5%)
9 (42.9%)
9 (42.9%)
3 (14.3%)
4.01 (0.46)
5.17 (5.97)
27.06 (5.66)
13.13 (1.01)
6936.84 (1816.35)
279.26 (50.96)
24.79 (12.20)
24.05 (14.40)
29.50 (9.65)
0.87 (0.39)
24.70 (3.72)
58.10 (6.32)
60.00
17 (81.0%)
10 (47.6%)
9 (42.9%)
2 (9.5%)
4.03 (0.45)
4.25 (4.53)
25.92 (6.79)
13.40 (0.96)
6662.50 (1209.34)
271.38 (49.72)
20.81 (4.28)
18.00 (6.30)
22.81 (6.00)
0.77 (0.17)
24.44 (3.20)
0.26
0.38
0.88
0.82
0.58
0.56
0.43
0.61
0.65
0.22
0.13
0.02
0.35
0.81
 Inflammatory markers in patients who participated in the 
study were on average above normal limits levels, IL-1 with a 
mean of 4.05 pg/ml (SD 0.45), IL-6 with a mean of 4.72 pg/ml 
(SD 5.28) and TNF-α with a mean of 26.50 pg/ml (SD 6.19). 
Other laboratory test like haematological liver and kidney 
function are also within normal limits. Average of BMI were 
slightly higher with a mean 24.57 (SD 3.43) showed excessive 
load on the joints, which that is one of risk factor for OA. Table 
1 shows there is no statistically significant difference between 
the groups of patients who get Mahkota Dewa fruit extract 
330 mg compared with a control group who received 7.5 mg 
meloxicam, so the research results obtained to avoid bias due 
to sample selection are not the same set of characteristics. 
However ureum level is significantly different, where the 
group Mahkota Dewa fruit extract 330 mg had higher level 
with mean 29.50 mg/dl (SD 9.65) compared to meloxicam 7.5 
mg, 22.81 mg/dl (SD 6.00) (p = 0.02), although the levels are 
still within normal limits.
 The data distribution was normally distributed on VAS and 
Lequesne index group analyzed by using parametric statistics. 
Reduction in VAS data (p = 0.009) were not normally 
distributed, and the data is non-parametric, analyzed by the 
Wilcoxon test. 
Table 2 Efficacy test after Mahkota Dewa fruit extract 
(Phaleria macrocarpa fructus) 330mg treatment compared to 
meloxicam 7.5mg at day 14
Variable
Day 14 
Phaleria macro-
carpa 330 mg
N = 19
Mean (SD)
Meloxicam 7.5 mg
N = 17
Mean (SD)
P value
VAS
Before
After
Decrease
Lequesne
Before
After
Decrease
IL-1  (pg/ml)
Before
After
Decrease
IL-6  (pg/ml)
Before
After
Decrease
TNF-α (pg/ml)
Before
After
Decrease
40.48 (15.65)
24.47 (10.66)
15.52 (10.39)
7.45 (2.87)
4.71 (2.58)
2.55 (1.94)
4.07 (0.46)
4.13 (0.63)
-0.06 (0.54)
5.17 (5.97)
6.26 (9.47)
-1.31 (8.16)
27.02 (5.66)
27.32 (3.99)
-0.26 (4.72)
36.75 (13.21)
19.71 (10.07)
16.47 (10.42)
6.85 (2.32)
3.77 (1.73)
3.03 (2.31)
4.04 (0.45)
3.98 (0.41)
-0.01 (0.25)
4.25 (4.53)
4.42 (5.26)
0.19 (5.88)
25.91 (6.79)
27.88 (7.01)
-2.99 (3.86)
0.42
0.18
0.78
0.47
0.21
0.51
0.82
0.39
0.72
0.58
0.48
0.53
0.56
0.77
0.07
 Table 2 shows that the mean VAS decrease after 14 days 
of Mahkota Dewa fruit extract 330 mg treatment was 15.52 
(SD 10.39) did not differ significantly with meloxicam 7.5 
mg 16.47 ( SD 10.42) (p = 0.78). The VAS mean decrease 
> 20 % so that it can be considered a significant reduction 
in the degree of pain. The mean decrease in Lequesne index 
after 14 days Mahkota Dewa fruit extract 330 mg was 2.55 
(SD 1.94) did not differ significantly with meloxicam 7.5 mg, 
3.03 (SD 2.31  ) (p = 0.51). Mahkota Dewa fruit extract 330 
mg equivalent to 7.5 mg of meloxicam in reducing the degree 
of pain as measured by VAS and Lequesne Index. The effect 
of decreasing the proinflammatory cytokine in the blood are 
IL–1 -0.06 pg/ml (SD 0.54) compared to -0.01 pg/ml (SD 0,25 
) ( p = 0.72 ), IL-6 -1.31 pg/ml (SD 8.16) compared to 0.19 
pg/ml (SD 5.88) (p = 0.53) and TNF-α -0.26 pg/ml (SD 4.72) 
compared to -2.99 pg/ml (SD 3.86) (p = 0.07).
Table 3 Efficacy test after Mahkota Dewa fruit extract 
(Phaleria macrocarpa fructus) 330mg treatment compared to 
meloxicam 7.5mg at day 28
Variable
Day 28
Phaleria macro-
carpa 330 mg
N = 19
Mean (SD)
Meloxicam 7.5 mg
N = 17
Mean (SD)
P value
VAS
Day 28
Decrease
Lequesne
Day 28
Decrease
22.37 (11.35)
17.63 (10.05)
3.97 (2.07)
3.29 (2.45)
18.35 (9.51)
17.82 (7.97)
3.41 (2.35)
3.38 (1.68)
0.26
0.95
0.45
0.89
 The mean reduction in VAS still continues since day one 
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to 28 days in the group of Mahkota Dewa fruit extract 330 mg 
amounted to 17.63 (SD 10.05) did not differ significantly with 
meloxicam 7.5 mg 17.82 (SD 7.97) (p = 0.95), it also in the 
Lequesne index to 28 days in the group Mahkota Dewa fruit 
extract 330 mg mean decrease of 3.29 (SD 2.45) did not differ 
significantly with meloxicam 7.5 mg of 3.38 (SD 1.68) (p = 
0.89). Mahkota Dewa fruit extract 330 mg is still giving the 
effect of lowering the degree of pain on day 28 of observation, 
despite being dismissed for 14 days.
 Side effect of NSAIDs are gastrointestinal symptoms such 
as nausea 5.9% (p = 0.28) and heartburn 23.5% (p = 0.03), 
and cause some subjects were excluded from the analysis, 
while Mahkota Dewa the fruit extract have no any complaint. 
In a safety testing show that Mahkota Dewa fruit extract 330 
mg is safe for consumption, because it does not interfere with 
liver function, renal function and hematology, and also blood 
pressure after taking the test material for 14 days. 
 After Mahkota Dewa fruit extract 330 mg treatment 
suspended for 14 days or at day 28 observation, when compared 
to meloxicam 7.5 mg, there is side effect on liver function, 
kidney function, and haematology. After day 28 observations, 
Hb of the subjects received 7.5 mg of meloxicam was decrease 
0.47 g/dl (SD 0.51) compared to the group Mahkota Dewa 
fruit extract 330 mg 0.07 g/dl (SD 0.52) (p = 0.03)
Discussion
The long term pain in osteoarthritis need medications to reduce 
pain, but with lower side effects. Some pain medications 
such as NSAIDs have side effects on the gastrointestinal 
and cardiovascular systems.45-48 The use of herbs that have 
analgesic effect, is an option because of its low side effects. 
Some of the herbs have been studied to treat OA and is 
currently developed.49-55
 Mahkota dewa is a plant that is widely used by people 
as a traditional medicine to treat various conditions as 
antimicrobial, anti-hypertension, anti-diabetes, anti-
inflammatory and anti-cancer. These herbal drugs have other 
effects as an anti-oxidant that also may reduce pain in OA. 23,24
 In OA progression chondro process will be disrupted due 
to several components such as proinflammatory cytokines IL-
1, IL-6, TNF-α, metalloproteinase enzymes, and also the role 
of oxidative stress due to Reactive Oxygen Species (ROS). 
56,57
 Inflammation and cartilage degradation is one of the 
hypotheses of the pathogenesis of OA. Inflammation is 
caused by arachidonic acid metabolism and the role of 
various enzyme. While cartilage degradation is caused by an 
imbalance of proteases and protease inhibitors that leads to 
excessive degradation of cartilage matrix. 2  Oxidative stress 
causes damage to mitochondria that plays a role in the aging 
process, apoptosis, impaired function and tissue degeneration. 
Oxygen free radicals can penetrate into the cartilage and 
chondrocyte cells in vitro, although the actual chondrocyte 
cells can remain alive in a state without oxygen under 
normal circumstances, because it does not contain blood 
vessels. Chondrocyte metabolism itself is done anaerobically. 
Mitochondrial function in chondrocyte cells thought to 
prevent free radicals into the chondrocyte cells. Free radicals 
are already entered into the chondrocyte itself will result in a 
decrease in the synthesis of extracellular matrix resulting in 
thinning of the joints and improve joint calcification resulting 
in the formation of osteophytes. It also will play a role in 
cell apoptosis of chondrocytes. Mitochondria have their own 
chromosome is a genetic component in cell metabolism. 
The presence of genetic mutations will lead to a more rapid 
degenerative diseases, which will accelerate the occurrence of 
OA at a younger age. 56,57
 Pain that occurs in OA caused by three things: the 
inflammatory, ischemic and oxidative stress. Super oxide 
(SO) as free radicals also have an influence on tissue damage 
joints and cause pain. Phaleria macrocarpa also known to 
have antioxidant effects, therefore, anti-pain mechanisms 
presumably through suppression of this free radical oxidation 
pathway. 56,57
 The degradation of matrix molecules is actually a part 
of the remodelling process in the growth, development and 
joint matrix turnover. The process is actually a physiological 
process, which is regulated by various cytokines, growth 
factors, and hormones that regulate the synthesis of proteinase 
inhibitors and thus are in a balanced state. Excessive proteolysis 
is a pathological process resulting from an imbalance between 
proteinases (MMPs) and inhibitors (TIMPs). If there is more 
matrix destruction, it will be a lot of fragments that have been 
unraveled as collagen, proteoglycans and calcium crystals, 
regardless of the synovium space, and cause inflammatory 
responses, the production of prostaglandins as the end result 
will be more and more so that the effect of pain will increase. 
Effects of prostaglandins alone which can lead to vasodilation 
of blood vessels, increase vascular permeability, cause pain 
with bradykinin potentiating effect, activating lymphocytes, 
platelet aggregation, bone resorption, and T-cell suppression. 
Bone resorption that occurs will cause fragments of calcium 
such as calcium pyrophosphate crystals, hidroxiapatit, and 
calcium phosphates went into the synovium. The degree of 
inflammatory response as a result of this study is usually mild.
Pain  occurs not only from the experience of OA joints, 
because the actual joint cartilage does not contain nerves and 
vessels, but pain can also come from tissue around the joints, 
such as tendinitis, bursitis, ischemic subchondral bone, muscle 
spasm, osteophytes, psychic, ligament disruption, and others. 
Therefore, the degree of pain reduction at Mahkota Dewa fruit 
extract 330 mg apart due to anti-inflammatory effects may 
be caused by the effects of antioxidants, the effects of other 
active substances are not known and may also have the effect 
of plasebo.58 – 60 
 This study showed no difference in inflammatory 
markers found in the serum of patients with OA who have 
given good treatment with Mahkota Dewa fruit extract 330 
mg and Meloxicam 7.5 mg, although the degree of pain was 
reduced. The cause is probably due to the lack of high-dose 
or measurement of inflammatory markers IL-1, IL-6, TNF-α 
in OA should not be taken from the serum but directly from 
synovial fluid because there is no significant relationship 
between systemic inflammatory OA with local inflammation. 
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In the Framingham cohort study, years between 1998-2005 
in 1235 obtained subject there was no significant relationship 
between markers of inflammation in OA.17 Placebo only 
actually has the effect to reduce levels of pain that is quite 
effective in OA. 30 In the other study found that the mean 
TNF-α and IL-1β levels were lower in chronic OA compared 
with acute OA.40 This differs from the type of inflammatory 
rheumatic diseases such as rheumatoid arthritis else (RA) 
which can be found higher levels of TNF-α, IL-6 and IL-1 
in the serum. EULAR recommendations also provide non-
pharmacological therapy in patients with a diagnosis of OA in 
addition to therapy with multiple drugs. 61
 Experimental research of traditional medicinal native 
plants in Indonesia, Mahkota Dewa fruit extract 330 mg 
given for 14 days in patients with a diagnosis of osteoarthritis 
showed effects can reduce pain by measurement of pain by 
VAS and Lequesne index. Patients with OA more than 60 years 
of age who may have renal impairment and cardiovascular 
disorders when NSAIDs treatment would be very dangerous 
can be given this treatment. Mahkota Dewa fruit extract is an 
therapeutic option for OA to reduce the degree of pain yet safe 
for the elderly.
 The incidence of side effects of Mahkota Dewa fruit 
extract 330 mg against haematological, liver function, kidney 
function, or the blood pressure in the observation of the day 
14 and 28 are not found. This shows that the mahkota of dewa 
fruit extract is quite safe. LD50 Mahkota dewa extract in mice 
is greater than 1500 mg/kg bw. There were no significant 
differences between the groups in toxicity in experimental 
animals given the extract preparations Mahkota Dewa than 
the control group.19
 On day 28 observations obtained significant reduction in 
Hb subjects who received 7.5 mg of meloxicam for 14 days was 
0.47 g/dl (SD 0.51), this shows the long-term administration 
of NSAIDs for more than 14 days can lead to a decrease Hb 
due to hidden gastrointestinal bleeding in a person over the 
age of 60 years as the average age of the study subjects.
Limitation of this study are time of this study was conducted 
with only a two-week observation period where  as in studies 
using herbs, the new effect can be seen in a longer time around 
more than three weeks. Measurement of proinflammatory 
markers IL-1, IL-6 and TNF-α in two weeks has not been able 
to show a decrease in the blood levels, because the clinical 
symptoms will disappear earlier than the marker. In OA 
difficult to find increased inflammatory markers in the blood, 
but in the synovial fluid it can be higher than in the blood 
so that the examination in this study did not show significant 
results.
Conclusion
The conclusion of this study is Mahkota Dewa fruit extract 
(Phaleria macrocarpa fructus) 330 mg reduces the degree of 
pain in OA patients as same as meloxicam 7.5 mg. Mahkota 
Dewa fruit extract 330 mg does not reduce levels of IL-1, IL-
6, TNF-α in patients with OA as well as the administration of 
meloxicam 7.5 mg. Mahkota Dewa fruit extract 330 mg does 
not impair kidney function, liver function and haematologic 
parameters in patients with OA. Further research needs to be 
done about the content of some active substances Phaleria 
macrocarpa which acts as both an anti-inflammatory, and other 
effects that may influence the degree of pain decrease. Further 
research need to do to find the effects of Phaleria macrocarpa 
on levels of IL-1, IL-6 and TNF-α in the synovial tissue or 
joint fluid in different doses. 
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